Home > Healthcare IT > Carcinoid Syndrome Diarrhea Treatment Market Outlook, Size to 2026
Straits Research

Carcinoid Syndrome Diarrhea Treatment Market

Carcinoid Syndrome Diarrhea Treatment Market: Information by Treatment, Distribution Channel (Hospital, Retail and Online Pharmacies), End User), and Region — Forecast till 2026

Table of Content Download Sample

Market Overview

The carcinoid syndrome diarrhea treatment market size is expected to grow at a healthy CAGR of 13.2% during the forecast period, 2019–2026.

Carcinoid syndrome diarrhea is caused by a carcinoid tumor that secretes serotonin and other chemicals into patients’ bloodstream, which cause diarrhea in 80% incidences. Complications of uncontrolled diarrhea include malnutrition, weight loss, dehydration, and electrolyte imbalance. Signs and symptoms of carcinoid syndrome include flushing of the face, asthma caused due to vasoconstriction, debilitating diarrhea, intestinal bleeding, fast heartbeat, shortness of breath, sweating, and unexplained weight gain.

Carcinoid tumors, also known as metastatic neuroendocrine tumors, are rare and slow developing tumors that predominantly occur in the gastrointestinal tract or lungs. According to the U.S. Food and Drug Administration (FDA), less than 10% of the population with carcinoid tumors develops symptoms of carcinoid syndrome.

Market Snapshot

market snapshot
Base Year
: 2017
Study Period
: 2016-2026
CAGR
: 13.2 %
Fastest Growing Market
: Asia Pacific
Largest Market
: North America
Market Size
: 12
Get more information on this report Download Sample Report

Market Dynamics

The increasing prevalence of carcinoid syndrome diarrhea is the leading factor that drives market growth. According to the National Organization for Rare Disorders (NORD), in the U.S., more than 27 incidences of carcinoid syndrome diarrhoea per million are detected every year. The prevalence rate is the same in male and female and gastrointestinal cases mostly occur in the middle-aged population.

On the other hand, low awareness hinders market growth in developing regions such as Asia Pacific and Latin America.

Segmental Analysis

The global carcinoid syndrome diarrhea treatment market has been segmented by treatment type, distribution channel, end user, and region.

On the basis of treatment type, the market has been segmented into chemotherapy, somatostatin analog (SSA) therapy, and oral therapy. The somatostatin analog (SSA) therapy segment is projected to hold a prominent market share, owing to the high effectiveness of this therapy in carcinoid syndrome diarrhea treatment.

On the basis of distribution channel, the carcinoid syndrome diarrhea treatment market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to account for a noteworthy market share, owing to the growing number of hospital pharmacies around the globe.

Based on end user, the carcinoid syndrome diarrhea treatment market has been segmented into hospitals, clinics, and cancer institutes and treatment centers. The cancer institutes segment is projected to gain a substantial market share, owing to the growing demand for specialized medical treatment.

Regional Analysis

By region, the global carcinoid syndrome diarrhea treatment market has been segmented into North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).

North America is expected to dominate the carcinoid syndrome diarrhea treatment market during the forecast period, owing to the increasing prevalence of carcinoid syndrome diarrhea and high healthcare expenditure in the region. The U.S. FDA is approving new orphan drugs for carcinoid syndrome diarrhea, which is expected to further support market growth in the region.

Europe is pegged to be the second largest carcinoid syndrome diarrhea treatment market globally, followed by Asia Pacific. Europe’s growing geriatric population, coupled with increasing investments in healthcare, is also expected to contribute to the growing demand for carcinoid syndrome diarrhea treatment. As of 2017, the geriatric population in Europe accounted for 19.4% of the region’s total population (Eurostat).

Asia Pacific is expected to observe significant growth in the global carcinoid syndrome diarrhea treatment market, owing to the increasing prevalence of respiratory diseases such as asthma, COPD, and rhinosinusitis, and high number of smokers in the region. According to the World Bank Group, smoking prevalence in India’s male population was 20.6% in 2016.

The LAMEA carcinoid syndrome diarrhea treatment market is expected to witness sluggish growth during the forecast period, owing to the poor healthcare infrastructure in Africa. However, growing urbanization, improving healthcare infrastructure, and high disposable income in Middle Eastern countries such as UAE, Saudi Arabia, and Kuwait, among others are projected to drive market growth to some extent.

Carcinoid Syndrome Diarrhea Treatment Market Regional Analysis
Regional Growth Insights Download Free Sample

Top Key Players of Carcinoid Syndrome Diarrhea Treatment Market

List of key carcinoid syndrome diarrhea treatment market companies profiled

  1. Lexicon Pharmaceuticals Inc.
  2. Novartis International AG (Sandoz) (Switzerland)
  3. Pharmascience Inc. (Canada)
  4. Omega Laboratories Ltd. (Canada)
  5. Teva Pharmaceutical Industries Ltd. (Israel)
  6. Mylan N.V. (U.S.)
  7. Ipsen Biopharmaceuticals Inc. (U.S.)
  8. Sirtex Medical Limited (Australia)
  9. BTG International Ltd. (U.K.)
  10. Wockhardt Ltd.

Report Scope

Report Metric Details
CAGR 13.2%
Forecast Period 2023-2031
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered
  1. By Treatment Type
    1. Chemotherapy
    2. Oral Therapy
    3. Somatostatin Analog (SSA) Therapy
  2. By Distribution Channel
    1. Hospital Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
  3. By End User
    1. Hospitals
    2. Clinics
    3. Cancer Research Institutes
Geographies Covered
  • North America
  • Europe
  • APAC
  • Middle East and Africa
  • LATAM

Carcinoid Syndrome Diarrhea Treatment Market Segmentation

By Treatment Type

  • Chemotherapy
  • Oral Therapy
  • Somatostatin Analog (SSA) Therapy

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User

  • Hospitals
  • Clinics
  • Cancer Research Institutes

By Region

  • North America
  • Europe
  • Latin America
  • Middle East and Africa

Frequently Asked Questions (FAQs)

What is the estimated growth rate (CAGR) of the Carcinoid Syndrome Diarrhea Treatment Market?
Carcinoid Syndrome Diarrhea Treatment Market size will grow at approx. CAGR of 13.2% during the forecast period.
Some of the top prominent players in Carcinoid Syndrome Diarrhea Treatment Market are, Lexicon Pharmaceuticals Inc., Novartis International AG (Sandoz) (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (U.S.), Ipsen Biopharmaceuticals Inc. (U.S.), Sirtex Medical Limited (Australia), BTG International Ltd. (U.K.),
  • Wockhardt Ltd., etc.
  • In the Carcinoid Syndrome Diarrhea Treatment Market, North America has established itself as the market leader with a significant market share.
    The Asia Pacific region is projected to exhibit the highest rate of growth in the Carcinoid Syndrome Diarrhea Treatment Market.
    The global Carcinoid Syndrome Diarrhea Treatment Market report is segmented as follows: By Treatment Type, By Distribution Channel, By End User
    Price Starts From
    USD 995

    Purchase Benefits

    • Eligible for a free updated report next year
    • Completely customizable scope
    • 30% discount on your next purchase
    • Dedicated account manager
    • Query resolution within 24 hours
    • Permission to print the report
    Want to learn more about recent trends and data ?
    They Already Trust Us :
    Veto-Pharma
    Nippon Becton Dickinson
    Merck
    Argon Medical Devices
    Abbott
    Johnson & Johnson
    Need Assistance?
    +1 646 905 0080 (U.S.)
    +44 203 695 0070 (U.K.)
    sales@straitsresearch.com

    Report Benefits

    • Develop business strategies by understanding the trends shaping and driving the Market.
    • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
    • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
    • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
    • Track sales in the global and country-specific Market.
    • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
    Report Snapshot
    Looking For Custom Report ?
    Check Our License Options :

    As featured on :

    clients
    Trusted by Fortune 500
    Over 30000+ subscribers